Q3 2024 Holdings
Filed 2024-11-14 | 81 holdings | $2.0B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Boston Scientific Corp(BSX) | COM | 101137107 | $80.6M | 962,000 | 4.1% |
| Dianthus Therapeutics Inc(DNTH) | COM | 252828108 | $79.9M | 2,917,231 | 4.1% |
| Intuitive Surgical Inc(ISRG) | COM NEW | 46120E602 | $72.8M | 148,200 | 3.7% |
| Natera Inc(NTRA) | COM | 632307104 | $70.6M | 556,400 | 3.6% |
| CG Oncology Inc(CGON) | COM | 156944100 | $62.5M | 1,656,000 | 3.2% |
| Acadia Healthcare Company in(ACHC) | COM | 00404A109 | $62.5M | 985,000 | 3.2% |
| Neurocrine Biosciences Inc(NBIX) | COM | 64125C109 | $53.0M | 460,000 | 2.7% |
| Unitedhealth Group Inc(UNH) | COM | 91324P102 | $51.1M | 87,400 | 2.6% |
| Jazz Pharmaceuticals PLC(JAZZ) | SHS USD | G50871105 | $48.0M | 431,000 | 2.4% |
| Syndax Pharmaceuticals Inc(SNDX) | COM | 87164F105 | $47.3M | 2,455,000 | 2.4% |
| Perspective Therapeutics Inc(CATX) | COM NEW | 46489V302 | $46.0M | 3,444,002 | 2.3% |
| Glaukos Corp(GKOS) | COM | 377322102 | $44.9M | 344,900 | 2.3% |
| Ideaya Biosciences Inc(IDYA) | COM | 45166A102 | $43.5M | 1,373,000 | 2.2% |
| Insmed Inc(INSM) | COM PAR $.01 | 457669307 | $43.2M | 592,000 | 2.2% |
| Thermo Fisher Scientific Inc(TMO) | COM | 883556102 | $42.4M | 68,600 | 2.2% |
| Tenet Healthcare Corp(THC) | COM NEW | 88033G407 | $42.0M | 253,000 | 2.1% |
| Ultragenyx Pharmaceutical in(RARE) | COM | 90400D108 | $41.8M | 752,000 | 2.1% |
| Humana Inc(HUM) | COM | 444859102 | $41.1M | 129,700 | 2.1% |
| Exact Sciences Corp(EXAS) | COM | 30063P105 | $40.1M | 588,000 | 2.0% |
| Illumina Inc(ILMN) | COM | 452327109 | $38.1M | 292,000 | 1.9% |
| Arvinas Inc(ARVN) | COM | 04335A105 | $36.9M | 1,497,000 | 1.9% |
| Revolution Medicines Inc(RVMD) | COM | 76155X100 | $35.8M | 790,000 | 1.8% |
| Centessa Pharmaceuticals PLC(CNTA) | SPONSORED ADS | 152309100 | $34.1M | 2,132,000 | 1.7% |
| Phathom Pharmaceuticals Inc(PHAT) | COM | 71722W107 | $32.6M | 1,804,493 | 1.7% |
| Xenon Pharmaceuticals Inc(XENE) | COM | 98420N105 | $32.2M | 818,000 | 1.6% |
| Avantor Inc(AVTR) | COM | 05352A100 | $31.9M | 1,235,000 | 1.6% |
| Blueprint Medicines Corp(2L9) | COM | 09627Y109 | $29.1M | 315,000 | 1.5% |
| Mirum Pharmaceuticals Inc(MIRM) | COM | 604749101 | $28.5M | 731,104 | 1.5% |
| Surgery Partners Inc(SGRY) | COM | 86881A100 | $26.7M | 827,000 | 1.4% |
| Axsome Therapeutics Inc(AXSM) | COM | 05464T104 | $26.6M | 296,100 | 1.4% |
| Danaher Corporation(DHR) | COM | 235851102 | $26.4M | 95,000 | 1.3% |
| Janux Therapeutics Inc(JANX) | COM | 47103J105 | $25.5M | 562,000 | 1.3% |
| Neumora Therapeutics Inc.(NMRA) | COM | 640979100 | $23.8M | 1,800,000 | 1.2% |
| Kymera Therapeutics Inc(KYMR) | COM | 501575104 | $23.7M | 500,000 | 1.2% |
| Biohaven LTD(BHVN) | COM | G1110E107 | $23.2M | 465,000 | 1.2% |
| Biomarin Pharmaceutical Inc(BMRN) | COM | 09061G101 | $22.5M | 320,000 | 1.1% |
| Argenx SE(ARGX) | SPONSORED ADR | 04016X101 | $20.7M | 38,200 | 1.1% |
| Incyte Corp(INCY) | COM | 45337C102 | $20.4M | 308,110 | 1.0% |
| Abbvie Inc(ABBV) | COM | 00287Y109 | $19.7M | 100,000 | 1.0% |
| Oruka Therapeutics Inc(ORKA) | COM | 687604108 | $19.4M | 790,926 | 1.0% |
| Structure Therapeutics Inc(GPCR) | SPONSORED ADS | 86366E106 | $18.9M | 430,900 | 1.0% |
| Neurogene Inc(NGNE) | COM | 64135M105 | $17.8M | 425,041 | 0.9% |
| Terns Pharmaceuticals Inc(TERN) | COM | 880881107 | $17.8M | 2,133,872 | 0.9% |
| Ascendis Pharma A/S(ASND) | SPONSORED ADR | 04351P101 | $17.8M | 119,000 | 0.9% |
| Biontech SE(BNTX) | SPONSORED ADS | 09075V102 | $17.2M | 145,000 | 0.9% |
| Intra-Cellular Therapies Inc(ITCIEUR) | COM | 46116X101 | $17.0M | 233,000 | 0.9% |
| Keros Therapeutics Inc(KROS) | COM | 492327101 | $17.0M | 293,200 | 0.9% |
| Dexcom Inc(DXCM) | COM | 252131107 | $16.1M | 240,000 | 0.8% |
| Oric Pharmaceuticals Inc(ORIC) | COM | 68622P109 | $14.8M | 1,447,119 | 0.8% |
| Newamsterdam Pharma Company(NAMS) | ORDINARY SHARES | N62509109 | $14.8M | 889,700 | 0.8% |